1 min left
Liraglutide
Saxenda review: cost, effectiveness, and 2026 verdict
Saxenda (liraglutide 3.0mg) is a daily injection FDA-approved for chronic weight management.
0.0
/ 10
Bariatric medicine specialist1 min read
Starting price
$1,349/mo
cash pay
FDA status
FDA-approved
Brand drug
Format
Daily injection
Self-administered
Refund policy
Pharmacy-dependent
Rx drug — no refund
Timing
When does Saxenda start working?
- Days 1-7
Daily injection at 0.6 mg. Subtle appetite changes.
- Weeks 1-5
Daily titration: 0.6 → 1.2 → 1.8 → 2.4 → 3.0 mg by week 5. Nausea common at each step.
- Weeks 6-12
Maintenance 3.0 mg daily. Weight loss accelerates. SCALE cohort lost ~5% by week 12.
- Months 3-6
SCALE averaged 7-8% body weight loss at 6 months on 3.0 mg daily.
- Month 12+
SCALE averaged ~8% at 56 weeks. Most weight loss occurs in first 6 months.
Projection
What you might lose on Saxenda
Sourced from SCALE (NEJM 2015) mean weight loss of 8% body weight at 56 weeks. Individual results vary substantially; this is not a guarantee.
Projected loss at 56 weeks
18lbs
Range: 13-22 lbs
Projected weight
202lbs
8% of starting weight
Projection based on SCALE (NEJM 2015) mean outcomes. Real-world results vary by adherence, diet, exercise, comorbidities, and individual response. Not a medical recommendation.
Pros and cons
Saxenda pros and cons
Pros
- On-label FDA approval for chronic weight management since 2014
- Approved for ages 12+ (pediatric indication)
- Established long-term safety record
- Daily injection gives more dose flexibility
Cons
- Daily injection burden — most patients prefer weekly Wegovy or Zepbound
- Lower weight-loss efficacy than weekly GLP-1s (~8% vs ~15% for Wegovy)
- Increasingly de-prioritized on formularies
- PA approval often lower than Wegovy on identical criteria
- Black-box warning for MTC / MEN2
Check Saxenda coverage
Coverage by insurer
Tap your plan for prior authorization criteria, copay range, and step therapy rules.
Compare Saxenda with
One-tap side-by-side. Score + price + side-effect profile.
How Saxenda works through telehealth
Three steps from intake to delivery
- 01
Saxenda intake
Intake captures BMI, weight history, and prior weight-loss medication trials. Saxenda BMI threshold matches Wegovy (≥ 30 or ≥ 27 with comorbidity).
- 02
PA submission
Clinician submits PA. Saxenda PA approval is generally lower than Wegovy on identical criteria; many plans now prefer Wegovy. Manufacturer savings card brings copay to $25/mo for eligible.
- 03
Daily injection support
Saxenda is daily, not weekly. Daily titration 0.6 → 1.2 → 1.8 → 2.4 → 3.0 mg over 5 weeks. Daily injection burden is the dominant Saxenda adherence theme.
Manufacturer savings
Saxenda savings card: Saxenda Savings Card
Max savings
$200/mo (commercial)
Eligibility
Commercial insurance, no Medicare/Medicaid
Expiration
12 months from enrollment
Enrollment steps
Confirm commercial coverage
Saxenda savings card excludes government insurance.
Enroll at saxenda.com
Provide insurance card and Rx information online.
Present at pharmacy
Show card at first fill; pharmacist applies discount.
Re-enroll annually
Card expires 12 months from issuance.
Enroll at Saxenda Savings Card ↗Or call 1-844-372-9362
Best ways to get Saxenda in 2026
We tested 2 verified routes. Each wins on a different axis — pick by what matters to you.
Best for cash pay
NovoCare Direct
Novo Nordisk's direct channel. Saxenda is the only FDA-approved GLP-1 for adolescents 12-17.
- Mfg direct
- Daily injection format
- Pediatric indication (12+)
$469/mo
Check offerBest for adolescent care
Form Health
Saxenda's 12+ indication is rare in GLP-1 space. Form handles pediatric obesity protocols.
- MD + dietitian
- Pediatric protocols
- Insurance handling
$99/mo
Check offerAffiliate disclosure: we earn commission on outbound clicks but ranking order is set by our clinician-vetted methodology. Read policy.
Saxenda score breakdown
What you'll pay for Saxenda
Pick your insurance situation. Your monthly cost + best route update live.
Commercial insurance + savings card
$25/monthsave $1,324
Manufacturer copay card (most plans)
See offerEstimates only. Final out-of-pocket varies by plan tier, formulary, deductible status, and pharmacy.
Clinical trial data
What clinical trials show
Weight loss curve
-7.3%body weight at 15 mo
Start3mo6mo9mo12mo15mo
Source: SCALE Obesity trial
Side effect frequency (clinical trial)
- Nausea39%· resolves ~4mo
- Vomiting16%· resolves ~3mo
- Diarrhea21%· resolves ~3mo
- Constipation19%· resolves ~6mo
- Injection site reaction14%
- Hypoglycemia (T2D patients)23%
Most GI side effects resolve as your body adapts. Talk to your prescriber if persistent past expected resolution.
Saxenda side effects: frequency in clinical trials
Pooled rates from the FDA-approval pivotal trials. Most GI effects fade by month 3 as the body adapts.
| Side effect | Frequency | Severity | Typical resolution |
|---|---|---|---|
| Nausea | 39% | Common | ~4mo |
| Hypoglycemia (T2D patients) | 23% | Frequent | Variable |
| Diarrhea | 21% | Frequent | ~3mo |
| Constipation | 19% | Frequent | ~6mo |
| Vomiting | 16% | Frequent | ~3mo |
| Injection site reaction | 14% | Uncommon | Variable |
Source: Pooled phase 3 trial data. Individual response varies. Talk to your prescriber if effects persist past expected resolution.
Side-effect onset
When Saxenda side effects start and end
Typical onset and resolution window from pivotal trial data. Bars show the most-reported symptom timing; individual experience varies.
1
3
5
7
9
11
13
15
- Nausea39%
- Diarrhea21%
- Constipation19%
- Vomiting16%
- Headache14%
Mild peak
Moderate peak
Severe peak
What Saxenda looks like
Placeholder visuals. Real product imagery shipping pending DEA-compliant photo licensing.
Saxenda dose escalation timeline
Standard daily titration over 52 weeks. Your prescriber may adjust based on tolerance. Reduces GI side effects vs starting at full strength.
- Week 1 10.6mg
Daily injection, week 1.
- Week 2 21.2mg
Week 2.
- Week 3 31.8mg
Week 3.
- Week 4 42.4mg
Week 4.
- Week 53.0mgMaintenance
Maintenance dose. Continue daily.
Not medical advice. Final dosing decisions belong to your prescribing clinician.
Saxenda drug interaction checker
Pick the medications you currently take. We show known interactions with Saxenda. Editorial reference — your prescriber and pharmacist make the final call.
Warfarin
MajorGLP-1 delayed gastric emptying alters warfarin absorption variably. INR can shift up or down during titration weeks.
Mechanism: Slowed gastric emptying changes the rate (not extent) of warfarin absorption. Patients also typically experience reduced caloric intake → lower vitamin K consumption from leafy greens → INR drift.
Management: Check INR weekly for the first 4 weeks AND for 2 weeks after each dose escalation. Adjust warfarin dose conservatively. Avoid changing other anticoagulant choices on top of GLP-1 initiation.
Levothyroxine
MajorGLP-1s delay levothyroxine absorption AND increase its bioavailability — net effect is roughly 33% AUC increase. Patients may become slightly hyperthyroid if dose not reduced.
Mechanism: Slowed gastric emptying paradoxically increases levothyroxine AUC because absorption window is longer. Most patients see TSH drift downward (toward hyperthyroidism) by 2-3 months.
Management: Recheck TSH 6-8 weeks after starting any GLP-1, then at 3 and 6 months. Take levothyroxine on completely empty stomach (1 hr before food, 4 hrs from other meds) — same rule as without GLP-1.
Sulfonylureas (glipizide, glyburide, glimepiride) + Insulin
MajorAdding GLP-1 to sulfonylureas or insulin substantially increases hypoglycemia risk. Other diabetes meds need proactive dose reduction.
Mechanism: GLP-1s lower glucose. Stacking with insulinogenic drugs (sulfonylureas) or insulin itself causes hypoglycemia. Dose reduction is mandatory, not optional.
Management: BEFORE starting GLP-1: reduce sulfonylurea dose by 50%. Reduce basal insulin by 20%. Reduce mealtime insulin proportional to expected appetite reduction. Monitor blood glucose 4x daily during titration.
Statins (atorvastatin, rosuvastatin, simvastatin)
ModerateGLP-1s slightly delay statin absorption but clinical effect is minimal. As weight drops, LDL typically improves and statin dose may need reduction.
Mechanism: Delayed gastric emptying delays statin Cmax but total AUC is preserved. Therapeutic effect maintained. Major effect is weight-loss-driven LDL reduction → potential deprescribing opportunity.
Management: Continue statin during GLP-1 titration. Check lipid panel at 3 and 6 months. If LDL drops >40 mg/dL with weight loss, discuss dose reduction or de-escalation with prescriber.
Immunosuppressants (tacrolimus, cyclosporine, mycophenolate)
MajorNarrow-therapeutic-index immunosuppressants are at risk from GLP-1 gastric emptying delays. Trough levels can shift unpredictably.
Mechanism: Tacrolimus and cyclosporine have narrow therapeutic windows. Delayed absorption + altered first-pass metabolism shifts trough levels. Mycophenolate AUC can change.
Management: Coordinate GLP-1 initiation with transplant team. Check immunosuppressant trough levels at weeks 1, 2, 4, then monthly. Consider conservative titration (longer 0.25mg phase). Some transplant centers contraindicate GLP-1 in first year post-transplant.
Oral antibiotics (especially erythromycin, azithromycin)
ModerateSome oral antibiotics interact with GLP-1s through additive gastric motility effects, potentially worsening nausea or interfering with absorption.
Mechanism: Macrolides (erythromycin, azithromycin) themselves accelerate gastric emptying — opposite of GLP-1 effect. Net result is unpredictable. Some other antibiotics absorbed less reliably when gastric pH/motility altered.
Management: For short courses (5-10 days), continue both with careful symptom monitoring. For chronic prophylaxis, consult prescriber. Take antibiotics on same schedule each day. If severe nausea develops, separate GLP-1 dose by 1-2 days.
Not a substitute for pharmacist review. Always show your full med list to your prescribing physician.
Coverage in progress
We require a 12-section template before publishing. This page covers 1 of 12.
1/12
8%
- Bottom line
- How it works
- Who it's for
- Efficacy
- Side effects
- Dosing
- Cost
- Insurance
- Refund
- Switching
- Discontinuation
- FAQ
M
As bariatric medicine specialist, I check every claim on this review against FDA labeling, peer-reviewed trial data, and current clinical guidelines. If something's off, we publish a correction.
Marcus Chen, DO, ABOM
Verified medical reviewerBariatric medicine specialist
Editorial score breakdown
Six axes, one sentence each. No black-box rating — how we score.
- Effectiveness7.0/10
- Safety8.0/10
- Value4.0/10
- Accessibility6.0/10
- User experience6.0/10
- Trust8.5/10
Plan length calculator
Most providers discount longer commitments. Estimate effective monthly cost across plan lengths.
Effective monthly
$1349
Total at signup
$1349
Savings vs monthly
$0
Discount assumptions are based on common industry tiers (5% at 3 mo, 10% at 6 mo, 17% at 12 mo). Actual provider discounts vary — confirm at checkout.
Pros and cons
Pros
- ✓ Long FDA approval history (since 2014)
- ✓ Pediatric approval (age 12+)
Cons
- ✗ Daily injection vs weekly competitors
- ✗ Lower weight loss than semaglutide
In-depth review
1/12 sectionsCost — what you'll actually pay
From $1,349/monthly
Independently reviewed
Continue with Saxenda?
See current pricing and program details directly from the provider.
Independently reviewed
Ready to start with Saxenda?
Editorial review independent of affiliate status. Affiliate disclosure on every page.
Community signals
What Saxenda users are saying
Themes our editors observed across public forums, paraphrased from real-world discussion. Not clinical evidence; not curated to favor any provider.
- Adherencer/Saxenda
Daily injection burden is the dominant Saxenda discontinuation theme. Most users who tolerate it eventually ask their prescriber to switch to weekly Wegovy.
- Side effectsr/Saxenda
Saxenda nausea is described as more constant than Wegovy due to daily exposure. Less wave-like, more low-grade and persistent for the first 4-6 weeks.
From a reader
“The daily injection burden is real. I tolerated Saxenda but kept asking when Wegovy would be covered. Eventually it was. The weekly cadence is the single biggest reason I stayed on the class.”
Composite case drawn from reader emails and public forum themes. Name changed. BMI and timeline reflect typical reader outcomes. Not clinical evidence; individual results vary.
People also ask
Saxenda questions, clinician answered
Pharmacist tips
Pharmacist tips for Saxenda
Same injection time daily
Pick a consistent time. Morning works for most. Missed dose: take when remembered if same day; skip if next day already.
Rotate sites
Abdomen, upper thigh, back of upper arm. Rotate daily — never inject same spot two days in a row.
Refrigerate but warm before injecting
Cold liraglutide stings. Out of fridge 15-30 min before dose.
Slow titration if nausea is severe
Your prescriber may stretch the 5-week titration to 8-10 weeks if 1.8 mg or 2.4 mg trigger persistent nausea.
Plan to switch eventually
Most patients move to weekly Wegovy once insurance allows. Ask your prescriber about the switch pathway.
Hydrate daily
2-3 L. Daily exposure drives more cumulative dehydration risk than weekly drugs.
Before your appointment
Questions to ask your doctor about Saxenda
Bring this list to your appointment. Most prescribers appreciate the structure and it usually saves clinic time.
- My BMI is ___. Why Saxenda rather than weekly Wegovy or Zepbound?
- Is Saxenda covered by my plan and how does it compare to Wegovy?
- When can we switch from Saxenda to a weekly drug?
- How do we manage daily injection burden?
- What labs do you want at baseline, 3 months, and 6 months?
- How long do you expect me to be on this medication?
- When should I contact you between visits (red flags)?
- How does this interact with my current medications and supplements?
Regulatory transparency
FDA / regulatory actions we are tracking
- September 2025·FDA
Warning letters to telehealth GLP-1 advertisers
FDA issued warning letters to Hims & Hers and several compounding pharmacies over weight-loss advertising claims and compounded semaglutide / tirzepatide marketing post-shortage resolution. Editorial: providers featured here have been reviewed for compliance with current FDA rules.
Read the source ↗ - May 2026·FDA
Semaglutide and tirzepatide shortages declared resolved
FDA confirmed both molecules off the official shortage list. 503A and 503B compounding pharmacies can no longer compound semaglutide or tirzepatide except for documented individual medical-necessity cases. Patients on compounded GLP-1s should plan to transition to brand or off-label scripts.
Read the source ↗
We track regulatory actions and surface them publicly, even when they involve advertised partners. Editorial rankings reflect verification, not commission.
Limitations & uncertainties
What we still don’t know about Saxenda
Honest medicine acknowledges its uncertainties. These are the open questions where the evidence is still incomplete, evolving, or contested.
Inferior efficacy vs weekly agents
Saxenda (~8% weight loss) underperforms weekly semaglutide (~15%) and tirzepatide (~21%). It is increasingly a second-tier option.
Daily adherence burden
Daily injection reduces real-world adherence vs weekly drugs. Long-term persistence data reflect this drop-off.
Diminishing formulary support
Many plans now prefer Wegovy. Saxenda availability and coverage are narrowing, creating supply uncertainty.
References
Cited sources· Saxenda
- Pi-Sunyer X, Astrup A, Fujioka K, et al.. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE).New England Journal of Medicine2015.PubMed 26132939 ↗
Editorial corrections
Updates to Saxenda review
Dated record of factual corrections and material updates to this page. We publish corrections rather than silently edit. Trust signal, not legal compliance.
- 2026-05-26· All review pages
Added editorial blocks: weight-loss projection slider, savings card workflow, side-effect onset chart, FDA regulatory transparency, numbered citations, plateau diagnostic cross-link. Refreshed AI product photography to 1536x1024 editorial-grade renders.
- 2026-05-15· All review pages
Added inline Jargon tooltip system across editorial body. Glossary appendix shows medical terms used per drug.
- 2026-04-12· All review pages
FAQ schema (FAQPage JSON-LD) added per review. People-also-ask block cross-links to Q&A library.
Medical glossary
Terms used in this Saxenda review
Quick reference for medical and regulatory terms above. Each term links to a longer explainer if you want deeper context.
- GLP-1
- Glucagon-like peptide-1 receptor agonist — class of drugs that mimic a gut hormone to reduce appetite and slow stomach emptying.
- Liraglutide
- First-generation GLP-1 receptor agonist; active ingredient in Saxenda and Victoza.
- BMI
- Body mass index = weight (kg) / height (m)². Overweight: 25-29.9. Obese: ≥30. FDA threshold for Wegovy/Zepbound: BMI ≥30, or ≥27 with weight-related condition.
- Titration
- Gradual dose increase over weeks to build tolerance and minimize GI side effects. Typical GLP-1 schedule: 4-week steps up to the maintenance dose.
- Prior authorization
- Insurance step that requires your doctor to document medical necessity before the plan will cover the drug. Adds 3-14 days but is often required for GLP-1s.
- MTC
- Rare thyroid cancer; GLP-1s carry an FDA black-box warning for personal or family history of MTC or MEN 2.
About this review
Was this useful?
Compare these alternatives
Other products in the same category, ranked by our editorial score.
Related reading